Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
1579 patients, 974 underwent RP and 605 enrolled on AS.
I · Intervention 중재 / 시술
RP and 605 enrolled on AS
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
A high Decipher score was associated with a higher risk of recurrence after RP for both v1.1 and v1.0. In summary, Decipher v1.1 scores tend to be lower than those of Decipher v1.0 and better predict the risk of a major biopsy upgrade on AS.
Decipher is a 22-gene genomic risk classifier that utilizes a whole-transcriptome microarray assay to provide a score ranging from 0 to 1.
- p-value p < 0.01
APA
Raizenne BL, Shee K, et al. (2025). Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients.. European urology oncology, 8(5), 1221-1226. https://doi.org/10.1016/j.euo.2025.08.002
MLA
Raizenne BL, et al.. "Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients.." European urology oncology, vol. 8, no. 5, 2025, pp. 1221-1226.
PMID
40908182 ↗
Abstract 한글 요약
Decipher is a 22-gene genomic risk classifier that utilizes a whole-transcriptome microarray assay to provide a score ranging from 0 to 1. Recently, the individual gene scores that defined Decipher v1.0 were reweighted to define updated Decipher v1.1. Our objective was to assess the impact of that change in a large institutional cohort database with active surveillance (AS)- and radical prostatectomy (RP)-specific outcomes. The dual primary outcomes included a major biopsy upgrade to Gleason grade group ≥3 after AS and prostate cancer recurrence after RP. Of 1579 patients, 974 underwent RP and 605 enrolled on AS. Decipher v1.1 scores (median 0.34; interquartile range [IQR] 0.22, 0.50) were lower on biopsy than on Decipher v1.0 (median 0.45; IQR 0.34, 0.59; p < 0.01). A high Decipher v1.1 score was associated with a higher risk of a major biopsy upgrade on AS (>0.6 vs <0.4; hazard ratio 2.11 [95% confidence interval 1.14-3.89]), while Decipher v1.0 was not. The median Decipher scores on prostatectomy were 0.64 (v1.0) and 0.61 (v1.1). A high Decipher score was associated with a higher risk of recurrence after RP for both v1.1 and v1.0. In summary, Decipher v1.1 scores tend to be lower than those of Decipher v1.0 and better predict the risk of a major biopsy upgrade on AS.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.